固生堂(02273.HK)2024年度業績:營收同比增長30.1%,客户羣實現穩定增長
格隆匯3月31日丨固生堂(02273.HK)公佈年度業績,截至2024年12月31日止年度,公司收入為人民幣30.22億元,同比增長30.1%;毛利為人民幣9.09億元,同比增長29.9%;經調整溢利淨額為人民幣4.00億元,同比增長31.4%,擬派末期股息每股0.41港元。報吿期內,集團的客户羣實現穩定增長,證明集團的客户獲取及留存戰略有效。
截至2024年12月31日,集團在中國北京、上海、廣州、深圳、佛山、中山、福州、南京、蘇州、寧波、無錫、杭州、鄭州、温州、崑山、武漢、常熟、徐州、長沙及江陰擁有及經營78家醫療機構。此外,於報吿期內,集團亦將其醫療服務網絡拓展至海外市場,推廣高質量中醫醫療健康服務,增強中醫在海外的影響力。截至2024年12月31日,集團在新加坡擁有及經營一家醫療機構。截至2024年12月31日,集團所擁有及經營的所有醫療機構均為「固生堂」品牌下的私立營利性醫療機構。此外,截至2024年12月31日,集團擁有及經營多種線上渠道,包括官方網站、手機應用、官方微信公眾號及小程序。截至同日,集團亦擁有及經營多家線下藥房,用於銷售其醫療健康產品。同時,集團與多個第三方線上平台合作,以便客户在線預約線下服務。
於報吿期內,集團新設四家線下醫療機構,即上海固生堂長楓中醫門診部有限公司、蘇州吳江固生堂中醫診所有限公司、温州鹿城固生堂大南中醫門診部有限公司及無錫固生堂上馬墩中醫醫院有限公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.